96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

•TAF is a new prodrug of tenofovir developed to treat patients with chronic HBV. •A lower dose of TAF can be used because it delivers tenofovir more efficiently to hepatocytes than TDF. •At week 48, TAF had non-inferior efficacy to TDF with improved renal and bone safety. •Efficacy and safety results at week 96 confirm the 48-week results in both studies. Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to...